A Study to Investigate RO7200220 in Diabetic Macular Edema
Status:
Not yet recruiting
Trial end date:
2024-01-15
Target enrollment:
Participant gender:
Summary
Study BP43445 is a phase II, multicenter, randomized, double-masked, active
comparator-controlled study to investigate the efficacy, safety, tolerability,
pharmacokinetics, and pharmacodynamics of RO7200220 administered intravitreally in
participants with diabetic macular edema. Only one eye will be chosen as the study eye. The
duration of the study will be 52 weeks.